Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2918338 | 0.71 | IDO1 (0.33) | IDO1 | |
| SCHEMBL18763496 | 0.70 | IDO1 (0.32) | IDO1CCNE1CDK2 | |
| SCHEMBL16608505 | 0.64 | CYP2A6 (0.36) | IDO1 | |
| SCHEMBL18763529 | 0.62 | IDO1 (0.34) | IDO1 | |
| SCHEMBL453372 | 0.57 | — | — | |
| SCHEMBL5044966 | 0.57 | IDO1 (0.36) | IDO1 | |
| SCHEMBL3621581 | 0.55 | — | — | |
| SCHEMBL5044838 | 0.55 | IDO1 (0.34) | IDO1 | |
| SCHEMBL8914 | 0.53 | — | — | |
| SCHEMBL14788249 | 0.53 | GRM5 (0.38) | IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022188841-A1 | HISTONE DEACETYLASE INHIBITOR AND APPLICATION THEREOF | 微境生物医药科技(上海)有限公司 | 2022-09-15 | — | — | WO | disclosed |
| US-10988476-B2 | Substituted pyrimidines as cyclin-dependent kinase inhibitors | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2021-04-27 | — | — | US | disclosed |
| US-20200239470-A1 | Substituted Pyrimidine Compound for Treating Cancer | SHANGHAI PHARMACEUTICALS HOLDING CO LTD (CN) | 2020-07-30 | — | — | US | disclosed |
| EP-3191483-B1 | COMPOUNDS AS CRTH2 ANTAGONIST AND USES THEREOF | NORTH & SOUTH BROTHER PHARMACY INVESTMENT CO LTD (CN) | 2020-06-10 | — | — | EP | disclosed |
| US-10662186-B2 | Substituted pyrimidines as cyclin-dependent kinase inhibitors | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2020-05-26 | — | — | US | disclosed |
| WO-2019174533-A1 | SMALL MOLECULE PD-1/PD-L1 INHIBITOR AND USE THEREOF IN DRUGS | 广东东阳光药业有限公司 | 2019-09-19 | — | — | WO | disclosed |
| EP-3169671-B1 | 1-(5-(TERT.-BUTYL)ISOXAZOL-3-YL)-3-(4-((PHENYL)ETHYNYL)PHENYL)UREA DERIVATIVES AND RELATED COMPOUNDS AS FLT3 INHIBITORS FOR TREATING CANCER | SUNSHINE LAKE PHARMA CO LTD (CN) | 2019-08-21 | — | — | EP | disclosed |
| US-20190010153-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUND, AS WELL AS PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2019-01-10 | — | — | US | disclosed |
| EP-3398947-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUND, AS WELL AS PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND APPLICATION THEREOF | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2018-11-07 | — | — | EP | disclosed |
| US-10065934-B2 | Substituted urea derivatives and pharmaceutical uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-09-04 | — | — | US | disclosed |
| US-9951010-B2 | Compounds as CRTH2 antagonist and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-04-24 | — | — | US | disclosed |
| US-20170267634-A1 | COMPOUNDS AS CRTH2 ANTAGONIST AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-09-21 | — | — | US | disclosed |
| US-20170114032-A1 | SUBSTITUTED UREA DERIVATIVES AND PHARMACEUTICAL USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239470-A1 | Substituted Pyrimidine Compound for Treating Cancer | DPYD, TYMP, TYMS | IDO1 1302/4885CCNE1 674/4885CDK2 112/4885 |
| US-10662186-B2 | Substituted pyrimidines as cyclin-dependent kinase inhibitors | CDK6, CDK4, CCNI | IDO1 1975/4885CCNE1 35/4885CDK2 6/4885 |
| US-20190010153-A1 | NITROGEN-CONTAINING FUSED HETEROCYCLIC COMPOUND, AS WELL AS PREPARATION METHOD, INTERMEDIATE, COMPOSITION AND APPLICATION THEREOF | CDK6, CDK4, CCNI | IDO1 1878/4885CCNE1 33/4885CDK2 13/4885 |
| US-20170114032-A1 | SUBSTITUTED UREA DERIVATIVES AND PHARMACEUTICAL USES THEREOF | ULK2, ULK3, ULK1 | IDO1 4020/4885CCNE1 800/4885CDK2 23/4885 |
| US-10988476-B2 | Substituted pyrimidines as cyclin-dependent kinase inhibitors | CDK1, CCNI, CDK2 | IDO1 1643/4885CCNE1 33/4885CDK2 3/4885 |
| US-10065934-B2 | Substituted urea derivatives and pharmaceutical uses thereof | ULK2, ULK3, ULK1 | IDO1 4020/4885CCNE1 800/4885CDK2 23/4885 |
| US-20170267634-A1 | COMPOUNDS AS CRTH2 ANTAGONIST AND USES THEREOF | HRH2, PTGDR2, HRH1 | IDO1 818/4885CCNE1 1993/4885CDK2 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.